FindTrial
Sign In

GC4419

DRUG6 trials

Sponsors

Galera Therapeutics, Inc.

Conditions

Covid19HealthyHealthy VolunteersPancreatic CancerRenal ImpairmentSARS-CoV-2 InfectionSquamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the Oropharynx

Phase 1

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
CompletedNCT01921426
Galera Therapeutics, Inc.Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Start: 2013-08-31End: 2016-08-31Target: 30Updated: 2016-09-22
A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects
CompletedNCT03163173
Galera Therapeutics, Inc.Healthy, Healthy Volunteers
Start: 2017-08-14End: 2017-10-13Updated: 2017-11-17
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
CompletedNCT03340974
Galera Therapeutics, Inc.Pancreatic Cancer, Stereotactic Body Radiation Therapy
Start: 2018-02-12End: 2021-05-26Updated: 2023-12-15
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects
CompletedNCT03792971
Galera Therapeutics, Inc.Healthy
Start: 2019-02-10End: 2019-02-15Updated: 2019-06-19
Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419
CompletedNCT05412472
Galera Therapeutics, Inc.Renal Impairment
Start: 2019-04-04End: 2021-04-06Updated: 2022-06-09

Phase 2

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
TerminatedNCT04555096
Galera Therapeutics, Inc.Covid19, SARS-CoV-2 Infection
Start: 2020-09-09End: 2021-05-28Updated: 2022-03-18

Related Papers

Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.
2023-12-0120 citations
Mitochondrial Oxidative Metabolism: An Emerging Therapeutic Target to Improve CKD Outcomes.
2023-05-2911 citations
Avasopasem manganese synergizes with hypofractionated radiation to ablate tumors through the generation of hydrogen peroxide.
2021-05-0132 citations
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
Antioxidants2020-10-1014 citations
Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.
Journal of Clinical Oncology2020-05-202 citations
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
Journal of Clinical Oncology2019-10-16118 citations
Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.
Journal of Clinical Oncology2019-05-202 citations
Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).
Journal of Clinical Oncology2016-05-203 citations